Is Biohaven Pharmaceutical Stock a Good Investment?
Biohaven Pharmaceutical Investment Advice | BHVN |
- Examine Biohaven Pharmaceutical's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Biohaven Pharmaceutical's leadership team and their track record. Good management can help Biohaven Pharmaceutical navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Biohaven Pharmaceutical's business and its evolving consumer preferences.
- Compare Biohaven Pharmaceutical's performance and market position to its competitors. Analyze how Biohaven Pharmaceutical is positioned in terms of product offerings, innovation, and market share.
- Check if Biohaven Pharmaceutical pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Biohaven Pharmaceutical's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Biohaven Pharmaceutical Holding stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Biohaven Pharmaceutical Holding is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Biohaven Pharmaceutical Stock
Researching Biohaven Pharmaceutical's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 92.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 9.28. Biohaven Pharmaceutical had not issued any dividends in recent years.
To determine if Biohaven Pharmaceutical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biohaven Pharmaceutical's research are outlined below:
| Biohaven Pharmaceutical generated a negative expected return over the last 90 days | |
| Biohaven Pharmaceutical has high historical volatility and very poor performance | |
| Biohaven Pharmaceutical Holding currently holds 32.78 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the company is not taking enough advantage from borrowing. Biohaven Pharmaceutical has a current ratio of 0.7, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Biohaven Pharmaceutical's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (846.42 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biohaven Pharmaceutical Holding currently holds about 23.21 M in cash with (582.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.48. | |
| Biohaven Pharmaceutical has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of Biohaven Pharmaceutical shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Biohaven stock hits 52-week low at 26.7 amid market challenges - Investing.com India |
Biohaven Pharmaceutical Quarterly Good Will |
|
Biohaven Pharmaceutical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biohaven Pharmaceutical Holding. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biohaven Pharmaceutical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Biohaven Pharmaceutical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Biohaven Pharmaceutical's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-02-28 | 2018-12-31 | -1.21 | -1.34 | -0.13 | 10 | ||
2023-11-14 | 2023-09-30 | -1.34 | -1.5 | -0.16 | 11 | ||
2018-08-14 | 2018-06-30 | -1.18 | -1.01 | 0.17 | 14 | ||
2024-11-13 | 2024-09-30 | -1.5506 | -1.74 | -0.1894 | 12 | ||
2025-03-03 | 2024-12-31 | -1.4712 | -1.71 | -0.2388 | 16 | ||
2023-05-12 | 2023-03-31 | -1.41 | -1.03 | 0.38 | 26 | ||
2020-11-09 | 2020-09-30 | -2.89 | -3.27 | -0.38 | 13 | ||
2024-02-29 | 2023-12-31 | -1.41 | -1.81 | -0.4 | 28 |
Know Biohaven Pharmaceutical's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biohaven Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biohaven Pharmaceutical Holding backward and forwards among themselves. Biohaven Pharmaceutical's institutional investor refers to the entity that pools money to purchase Biohaven Pharmaceutical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-12-31 | 2 M | Geode Capital Management, Llc | 2024-12-31 | 1.9 M | Citadel Advisors Llc | 2024-12-31 | 1.7 M | Armistice Capital, Llc | 2024-12-31 | 1.7 M | Holocene Advisors, Lp | 2024-12-31 | 1.1 M | Schmeidler A R & Co Inc | 2024-12-31 | 1 M | Brown Advisory Holdings Inc | 2024-12-31 | 975.6 K | Point72 Asset Management, L.p. | 2024-12-31 | 923 K | Nuveen Asset Management, Llc | 2024-12-31 | 919.2 K | Vanguard Group Inc | 2024-12-31 | 8.4 M | Blackrock Inc | 2024-12-31 | 7.7 M |
Biohaven Pharmaceutical's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.82 B.Market Cap |
|
Biohaven Pharmaceutical's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.42) | (1.49) | |
| Return On Capital Employed | (1.92) | (2.02) | |
| Return On Assets | (1.38) | (1.44) | |
| Return On Equity | (2.00) | (1.90) |
Determining Biohaven Pharmaceutical's profitability involves analyzing its financial statements and using various financial metrics to determine if Biohaven Pharmaceutical is a good buy. For example, gross profit margin measures Biohaven Pharmaceutical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biohaven Pharmaceutical's profitability and make more informed investment decisions.
Evaluate Biohaven Pharmaceutical's management efficiency
Biohaven Pharmaceutical has return on total asset (ROA) of (0.9685) % which means that it has lost $0.9685 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9883) %, meaning that it created substantial loss on money invested by shareholders. Biohaven Pharmaceutical's management efficiency ratios could be used to measure how well Biohaven Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of March 2025, Return On Tangible Assets is likely to drop to -1.49. In addition to that, Return On Capital Employed is likely to drop to -2.02. At this time, Biohaven Pharmaceutical's Non Currrent Assets Other are very stable compared to the past year. As of the 29th of March 2025, Net Tangible Assets is likely to grow to about 626.3 M, while Total Assets are likely to drop about 388.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.64 | 3.64 | |
| Tangible Book Value Per Share | 4.42 | 3.30 | |
| Enterprise Value Over EBITDA | (3.77) | (3.96) | |
| Price Book Value Ratio | 8.05 | 8.45 | |
| Enterprise Value Multiple | (3.77) | (3.96) | |
| Price Fair Value | 8.05 | 8.45 | |
| Enterprise Value | 3.3 B | 3.5 B |
The leadership approach at Biohaven Pharmaceutical's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 3.909 |
Basic technical analysis of Biohaven Stock
As of the 29th of March, Biohaven Pharmaceutical shows the Risk Adjusted Performance of (0.07), mean deviation of 2.68, and Standard Deviation of 3.78. Biohaven Pharmaceutical technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Biohaven Pharmaceutical's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biohaven Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biohaven Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biohaven Pharmaceutical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biohaven Pharmaceutical's Outstanding Corporate Bonds
Biohaven Pharmaceutical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biohaven Pharmaceutical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biohaven bonds can be classified according to their maturity, which is the date when Biohaven Pharmaceutical Holding has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Biohaven Pharmaceutical's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Biohaven Pharmaceutical's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.14) | |||
| Mean Deviation | 2.68 | |||
| Coefficient Of Variation | (1,114) | |||
| Standard Deviation | 3.78 | |||
| Variance | 14.26 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.22) | |||
| Total Risk Alpha | (0.11) | |||
| Treynor Ratio | (0.15) | |||
| Maximum Drawdown | 24.96 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 4.85 | |||
| Skewness | (0.13) | |||
| Kurtosis | 2.68 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.14) | |||
| Mean Deviation | 2.68 | |||
| Coefficient Of Variation | (1,114) | |||
| Standard Deviation | 3.78 | |||
| Variance | 14.26 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.22) | |||
| Total Risk Alpha | (0.11) | |||
| Treynor Ratio | (0.15) | |||
| Maximum Drawdown | 24.96 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 4.85 | |||
| Skewness | (0.13) | |||
| Kurtosis | 2.68 |
Consider Biohaven Pharmaceutical's intraday indicators
Biohaven Pharmaceutical intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biohaven Pharmaceutical stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 73818.91 | |||
| Daily Balance Of Power | (0.38) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 27.54 | |||
| Day Typical Price | 27.57 | |||
| Price Action Indicator | (0.26) | |||
| Period Momentum Indicator | (0.74) | |||
| Relative Strength Index | 44.91 |
Biohaven Pharmaceutical Corporate Filings
| 18th of March 2025 Other Reports | ViewVerify | |
| 5th of March 2025 Other Reports | ViewVerify | |
10K | 3rd of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Biohaven Stock media impact
Far too much social signal, news, headlines, and media speculation about Biohaven Pharmaceutical that are available to investors today. That information is available publicly through Biohaven media outlets and privately through word of mouth or via Biohaven internal channels. However, regardless of the origin, that massive amount of Biohaven data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biohaven Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biohaven Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biohaven Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biohaven Pharmaceutical alpha.
Biohaven Pharmaceutical Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Biohaven Pharmaceutical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Biohaven Pharmaceutical Historical Investor Sentiment
Investor biases related to Biohaven Pharmaceutical's public news can be used to forecast risks associated with an investment in Biohaven. The trend in average sentiment can be used to explain how an investor holding Biohaven can time the market purely based on public headlines and social activities around Biohaven Pharmaceutical Holding. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Biohaven Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Biohaven Pharmaceutical and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Biohaven Pharmaceutical news discussions. The higher the estimate score, the more favorable the investor's outlook on Biohaven Pharmaceutical.
Biohaven Pharmaceutical Maximum Pain Price Across May 16th 2025 Option Contracts
Biohaven Pharmaceutical's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Biohaven Pharmaceutical close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Biohaven Pharmaceutical's options.
Biohaven Pharmaceutical Corporate Directors
| John Childs | Independent Director | Profile | |
| Robert Hugin | Independent Director | Profile | |
| Michael Heffernan | Lead Independent Director | Profile | |
| Julia Gregory | Independent Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Biohaven Pharmaceutical's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.